We’re developing targeted therapies to lower LDL-cholesterol for patients not adequately treated with current lipid-modifying therapies.

Learn More


Esperion is a late-stage pharmaceutical company focused on developing and commercializing non-statin, convenient, complementary, consistent, once-daily, oral, LDL-C lowering therapies for the treatment of patients with hypercholesterolemia.

learn more


Reflecting on a Focused 2017 and Looking Ahead to a Transformational 2018

The past year was marked by tremendous progress for our bempedoic acid-based franchise – perhaps most importantly the achievement of… more

Posted by mlowe@esperion.com

Delivering on the “Long Game”

I was recently approached by STAT to answer, “How do you balance your long-term goals for your company with the… more

Posted by mlowe@esperion.com

The Lipid Management Team Reflects on the ESC Congress; the World’s Largest Gathering of Cardiovascular Health Experts

The Lipid Management Team traveled to Barcelona last month to attend the European Society of Cardiology (ESC) Congress, the world’s… more

Posted by mlowe@esperion.com